Capricor Therapeutics, Inc.

CAPR

US14070B3096

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2025-06-20 pm EDT			5-day change	1st Jan Change
8.260 ^USD	-30.82%		-29.88%	-40.14%

Jun. 20	Capricor Therapeutics Announces Positive 4-Year Data from Hope-2 Open-Label Extension Study of Deramiocel in Duchenne Muscular Dystrophy	CI
Jun. 20	Capricor Reports Slower Disease Progression in 4-Year Duchenne Study	MT

Sector Update: Health Care Stocks Lower Monday Afternoon

Published on 05/05/2025 at 14:08

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Capricor Therapeutics, Inc.

Capricor Therapeutics Announces Positive 4-Year Data from Hope-2 Open-Label Extension Study of Deramiocel in Duchenne Muscular Dystrophy	Jun. 20	CI
Capricor Reports Slower Disease Progression in 4-Year Duchenne Study	Jun. 20	MT
Capricor Therapeutics' Deramiocel Wins FDA Orphan Drug Designation for Becker Muscular Dystrophy	Jun. 17	MT
Capricor Therapeutics' Becker Muscular Dystrophy Drug Gets Orphan Drug Designation in U.S.	Jun. 17	DJ
Capricor Therapeutics, Inc., Q1 2025 Earnings Call, May 13, 2025	Jun. 13
Capricor Therapeutics Announces the Successful Completion of the U.S. Food and Drug Administration's License Inspection of Its San Diego Manufacturing Facility	Jun. 12	CI
Capricor Therapeutics' Duchenne Therapy Facility Inspection Completed by FDA	Jun. 11	MT
Capricor Therapeutics Announces Key Regulatory Updates for Its Duchenne Muscular Dystrophy Program	Jun. 11	CI
Roth Capital Initiates Coverage on Capricor Therapeutics With Buy Rating	May. 20	MT
Capricor Therapeutics Reports First Quarter 2025 Financial Results And Provides Corporate Update	May. 13	RE
Capricor Therapeutics, Inc. Appoints Michael Binks as Chief Medical Officer	May. 13	CI
Capricor Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	May. 13	CI
Sector Update: Health Care Stocks Retreat Late Afternoon	May. 05	MT
US FDA to convene expert panel for Capricor Therapeutics' DMD cell therapy	May. 05	RE
Sector Update: Health Care Stocks Lower Monday Afternoon	May. 05	MT
Capricor Therapeutics Shares Fall as FDA Plans Panel Review for Duchenne Treatment	May. 05	MT
Capricor Therapeutics Announces Completion of Mid-Cycle Review Meeting with FDA on Deramiocel for the Treatment of Duchenne Muscular Dystrophy Cardiomyopathy	May. 05	CI
Earl Collier Not to Stand for Re-Election as Member of the Board of Capricor Therapeutics, Inc	Apr. 08	CI
Capricor Therapeutics Q4 Loss Widens, Revenue Decreases	Mar. 19	MT
Capricor Therapeutics, Inc., Q4 2024 Earnings Call, Mar 19, 2025	Mar. 19
Capricor Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024	Mar. 19	CI
Capricor Therapeutics Says 3-Year Data Show Deramiocel Slows Duchenne Muscular Dystrophy	Mar. 17	MT
Capricor Therapeutics, Inc. Announces Positive Data Demonstrating Long-Term Efficacy of Deramiocel for the Treatment of Duchenne Muscular Dystrophy	Mar. 17	CI
Capricor Therapeutics' Biologics License Application for Deramiocel Accepted by FDA	Mar. 10	MT
Capricor Therapeutics Shares Rise on FDA Priority Review	Mar. 04	DJ

Chart Capricor Therapeutics, Inc.

Duration

Period

CAPR: Dynamic Chart

Capricor Therapeutics, Inc. is a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases. The Company's program is focused on the development and commercialization of a cell therapy technology comprised of cardiosphere-derived cells (CDCs) for the treatment of Duchenne muscular dystrophy (DMD). Its lead product candidate, CAP-1002, is an allogeneic cardiac-derived cell therapy. CAP-1002 is advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy (DMD). CAP-1002 demonstrates immunomodulatory, antifibrotic, and regenerative actions specifically tailored for dystrophinopathies and heart disease. The Company leverages its exosome technology, using its StealthX platform in preclinical development focused on the areas of vaccinology, targeted delivery of oligonucleotides, proteins and small molecule therapeutics to potentially treat and prevent a diverse array of diseases.

Employees

160

Sector

Biotechnology & Medical Research

Calendar

Aug. 06 - Q2 2025 Earnings Release (Projected)

More about the company